Abstract
A wealth of evidence supports the broad therapeutic potential of NF-kappa B and EZH2 inhibitors as adjuvants for breast cancer treatment. We contribut......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
